hotspot -WSS

hotspot

author：fashion 2025-09-03 09:23:54 - browse：9

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： H5N1 bird flu found in pasteurized milk: what we know

hotspot

WSS

Health care needs a new profession: neuroimaging counseling

Flagship Pioneering launches a new biotech in two countries

Despite FDA concern, risk that CAR

Cell therapy fails to slow type 1 diabetes, but safety is established

The EPA's new lead rule: How one expert crunched the numbers

MassMutual is introducing free genetic testing for members

focus

hotspot

Lobbying power of AI, software-enabled devices

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

How to save PrEP access — and even expand it

Getting Alzheimer's drug Leqembi to patients can be a challenge

Anesthesiologist group: stop taking Ozempic before surgery

Dogs on Prozac: What pet anti

New air purifier tech could be key to improving indoor air quality

MassMutual is introducing free genetic testing for members

Medicare details structure of new drug price negotiation program

Flagship Pioneering launches a new biotech in two countries

entertainment

30 years of 'Listening to Prozac'

Bird flu in milk supply is likely coming from asymptomatic cows

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

FDA investigates CAR

Despite FDA concern, risk that CAR

The EPA's new lead rule: How one expert crunched the numbers

focus

leisure time

hotspot

focus